Vertex Pharmaceuticals Inc (VRTX)
Interest coverage
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -232,900 | -270,400 | -348,600 | 4,192,500 | 3,832,000 | 3,877,000 | 3,965,600 | 4,045,500 | 4,307,400 | 4,151,600 | 4,079,400 | 2,935,200 | 2,782,100 | 2,809,311 | 2,514,538 | 3,391,079 | 3,174,949 | 2,961,237 | 2,286,724 | 1,790,058 |
Interest expense (ttm) | US$ in thousands | 30,600 | 38,400 | 41,800 | 43,100 | 44,100 | 45,100 | 47,900 | 51,300 | 54,800 | 58,300 | 59,855 | 60,733 | 61,511 | 62,699 | 61,300 | 59,693 | 58,151 | 56,112 | 56,804 | 57,770 |
Interest coverage | -7.61 | -7.04 | -8.34 | 97.27 | 86.89 | 85.96 | 82.79 | 78.86 | 78.60 | 71.21 | 68.15 | 48.33 | 45.23 | 44.81 | 41.02 | 56.81 | 54.60 | 52.77 | 40.26 | 30.99 |
December 31, 2024 calculation
Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $-232,900K ÷ $30,600K
= -7.61
The interest coverage ratio indicates Vertex Pharmaceuticals Inc's ability to meet its interest obligations with its earnings before interest and taxes (EBIT). A higher interest coverage ratio is generally considered favorable as it suggests the company can easily cover its interest expenses.
Looking at the data provided, Vertex Pharmaceuticals Inc's interest coverage ratio has displayed some fluctuation over the periods. The ratio ranged from 30.99 in March 2020 to a peak of 97.27 in March 2024, which suggests a strong ability to cover interest payments with operating income during this period.
However, there were instances where the interest coverage ratio dropped below 1, specifically in June 2024, September 2024, and December 2024. This implies that in those particular quarters, Vertex Pharmaceuticals Inc may have had difficulty meeting its interest obligations with its earnings.
It is important to assess the reasons behind the significant decrease in the interest coverage ratio during those quarters to understand if it was due to temporary circumstances or if there are underlying issues that need to be addressed. Overall, while the company has shown a strong interest coverage ratio in many periods, attention should be paid to the quarters where the ratio fell below 1 to ensure the sustainability of the company's financial health.
Peer comparison
Dec 31, 2024
See also:
Vertex Pharmaceuticals Inc Interest Coverage (Quarterly Data)